Celltrion Pharm Inc
KOSDAQ:068760
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
43 581.3789
73 700
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| KR |
C
|
Celltrion Pharm Inc
KOSDAQ:068760
|
3.2T KRW |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
964.8B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.9B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
268.4B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
209.9B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
219B CHF |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.7T DKK |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
267.4B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
149.5B USD |
Loading...
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
94.6B EUR |
Loading...
|
Market Distribution
| Min | -163 055.6% |
| 30th Percentile | -2.2% |
| Median | 2.7% |
| 70th Percentile | 6.8% |
| Max | 22 874.8% |
Other Profitability Ratios
Celltrion Pharm Inc
Glance View
In the bustling world of pharmaceuticals, Celltrion Pharm Inc. has carved a niche for itself, leveraging innovation and strategic market positioning. Born out of South Korea, this dynamic player operates with a vision to transform the pharmaceutical landscape, particularly through its expertise in biosimilars and small molecule drugs. By focusing on cutting-edge research and development, Celltrion Pharm is able to produce high-quality, cost-effective alternatives to branded biologics, which are essential for treating diseases such as cancer and autoimmune disorders. With a comprehensive pipeline of biosimilar products, the company effectively taps into a growing demand, driven by global healthcare systems seeking cost-efficient therapeutics amidst rising healthcare expenditures. Celltrion Pharm's operational strategy extends beyond product innovation. It encompasses robust manufacturing infrastructure and a global distribution network that underscores its financial growth. By owning state-of-the-art production facilities, the company ensures both the scale and quality required to meet international benchmarks, which is pivotal in the highly regulated pharmaceutical industry. Furthermore, strategic alliances and partnerships bolster its market reach, ensuring that its products have strong footholds not just locally, but globally. Through these multifaceted endeavors—ranging from R&D to distribution—the company has positioned itself as a formidable force, achieving sustainable revenue streams by addressing critical healthcare needs and optimizing drug accessibility worldwide.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Celltrion Pharm Inc is 10.2%, which is above its 3-year median of 8.9%.
Over the last 3 years, Celltrion Pharm Inc’s Operating Margin has increased from 9.6% to 10.2%. During this period, it reached a low of 5.5% on Jun 30, 2024 and a high of 11.2% on Jun 30, 2023.